Patents by Inventor Cristina Bolzati
Cristina Bolzati has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220054663Abstract: The present invention relates to a labeling procedure for the incorporation, in mild reaction conditions, of sensitive and thermosensitive targeting molecules into a [99mTc(N)(PNP)]-based compound suitable for a kit formulation.Type: ApplicationFiled: September 2, 2021Publication date: February 24, 2022Applicant: BRACCO IMAGING SPAInventors: Cristina BOLZATI, Nicola SALVARESE, Fiorenzo REFOSCO, Simona GHIANI, Alessandro MAIOCCHI, Barbara SPOLAORE
-
Patent number: 11160886Abstract: The present invention relates to a labeling procedure for the incorporation, in mild reaction conditions, of sensitive and thermosensitive targeting molecules into a [99m Tc(N)(PNP)]-based compound suitable for a kit formulation.Type: GrantFiled: December 15, 2017Date of Patent: November 2, 2021Assignee: BRACCO IMAGING SPAInventors: Cristina Bolzati, Nicola Salvarese, Fiorenzo Refosco, Simona Ghiani, Alessandro Maiocchi, Barbara Spolaore
-
Publication number: 20200078479Abstract: The present invention relates to a labeling procedure for the incorporation, in mild reaction conditions, of sensitive and thermosensitive targeting molecules into a [99m Tc(N)(PNP)]-based compound suitable for a kit formulation.Type: ApplicationFiled: December 15, 2017Publication date: March 12, 2020Applicant: BRACCO IMAGING SPAInventors: Cristina BOLZATI, Nicola SALVARESE, Fiorenzo REFOSCO, Simona GHIANI, Alessandro MAIOCCHI, Barbara SPOLAORE
-
Patent number: 8182789Abstract: A bisphosphonoamine compound represented by the following formula (I): wherein R1, R2, R3, R4 and R5 are independently an alkyl group having 1 to 6 carbon atoms, and n is an integer of 1 to 6, is extremely useful as an intermediate for preparing a technetium nitride complex for radiodiagnostic imaging.Type: GrantFiled: January 20, 2006Date of Patent: May 22, 2012Assignee: Nihon Medi-Physics Co., Ltd.Inventors: Francesco Tisato, Fiorenzo Refosco, Cristina Bolzati, Stefania Agostini, Marina Porchia, Mario Cavazza-Ceccato, Shinji Tokunaga
-
Patent number: 7771704Abstract: The present invention provides radioactive metal heterocomplexes of formula (I): [(Me=N—R)L1L2]+Z? wherein Me, R, L1L2 and Z? have the meanings indicated in the description. The complexes include a trivalent radioactive metal-imido group, typically a technetium-or rhenium-imido group, strongly stabilized by the presence of an ancillary tridentate hetero-diphosphine ligand L1, which allows the formation of substitution-inert [(Me=N—R)L1] moieties. Such moieties are fixed in an intermediate [(Me=N—R)Y2L1)]+ compound which contains two labile, cispositioned, Y ligands, where Y is preferably an halide group. The latter are easily replaced by a bidentate ligand L2 to give the final [(Me=N—R)L1L2]+ Z?heterocomplexes. The complexes of the invention are useful for the preparation of radiopharmaceuticals: in fact, a bioactive fragment which confers biological target-seeking properties can be introduced either on the L2 framework or the imido R group.Type: GrantFiled: June 23, 2008Date of Patent: August 10, 2010Assignee: Bracco Imaging S.p.A.Inventors: Francesco Tisato, Cristina Bolzati, Marina Porchia, Fiorenzo Refosco
-
Publication number: 20100160615Abstract: A bisphosphonoaminc compound represented by the following formula (I): wherein R1, R2, R3, R4 and R5 are independently an alkyl group having 1 to 6 carbon atoms, and n is an integer of 1 to 6, is extremely useful as an intermediate for preparing a technetium nitride complex for radiodiagnostic imaging.Type: ApplicationFiled: January 20, 2006Publication date: June 24, 2010Applicant: NIHON MED-PHYSICS CO., LTD.Inventors: Francesco Tisato, Fiorenzo Refosco, Cristina Bolzati, Stefania Agostini, Marina Porchia, Mario Cavazza-Ceccato, Shinji Tokunaga
-
Patent number: 7445765Abstract: A radiopharmaceutical for diagnostic imaging containing as an active ingredient a technetium-99m nitride heterocomplex comprising technetium-99m nitride and two different ligands coordinated therewith, i.e., a bisphosphinoamine compound as a ? electron acceptor and a bidentate ligand as a ? electron donor and represented by the following formula (I): [99mTc(N)(PNP)(XY)]+ (I)wherein 99mTc(N) is technetium-99m nitride, PNP is a bisphosphinoamine compound and XY is a bidentate ligand, is markedly accumulated in heart and adrenal glands and hence is useful for radiodiagnostic imaging of heart and adrenal glands.Type: GrantFiled: July 25, 2001Date of Patent: November 4, 2008Assignee: Nihon Medi-Physics Co., Ltd.Inventors: Adriano Duatti, Cristina Bolzati, Licia Uccelli, Alessandra Boschi, Fiorenzo Refosco, Francesco Tisato
-
Publication number: 20080267868Abstract: A process for diagnostic imaging of heart or adrenal glands of a human being comprises administering to the human being a radiopharmaceutical containing as an active ingredient a technetium-99m nitride heterocomplex comprising technetium-99m nitride and two different ligands coordinated therewith, i.e., a bisphosphinoamine compound and a bidentate ligand and represented by the formula (1): [99mTc(N)(PNP)(XY)]+. In this formula, 99mTc(N) is technetium-99m nitride, PNP is a bisphosphinoamine compound and XY is a bidentate ligand as described in the specification. The compound of the formula is markedly accumulated in heart and adrenal glands and hence is used for radiodiagnostic imaging of heart and adrenal glands.Type: ApplicationFiled: August 9, 2007Publication date: October 30, 2008Applicant: Nihon Medi-Physics, Co., Ltd.Inventors: Adriano Duatti, Cristina Bolzati, Licia Uccelli, Alessandra Boschi, Fiorenzo Refosco, Francesco Tisato
-
Publication number: 20080267869Abstract: The present invention provides radioactive metal heterocomplexes of formula (I): [(Me=N—R)L1L2]+Z? (I), wherein Me, R, L1 L2 and Z? have the meanings indicated in the description. The complexes include a trivalent radioactive metal-imido group, typically a technetium- or rhenium-imido group, strongly stabilized by the presence of an ancillary tridentate hetero-diphosphine ligand L1, which allows the formation of substitution-inert [(Me=N—R)L1] moieties. Such moieties are fixed in an intermediate [(Me=N—R)Y2L1)]+ compound which contains two labile, cispositioned, Y ligands, where Y is preferably an halide group. The latter are easily replaced by a bidentate ligand L2 to give the final [(Me=N—R)L1L2]+ Z?heterocomplexes. The complexes of the invention are useful for the preparation of radiopharmaceuticals: in fact, a bioactive fragment which confers biological target-seeking properties can be introduced either on the L2 framework or the imido R group.Type: ApplicationFiled: June 23, 2008Publication date: October 30, 2008Applicant: BRACCO IMAGING S.P.A.Inventors: Francesco Tisato, Cristina Bolzati, Marina Porchia, Fiorenzo Refosco
-
Publication number: 20080226550Abstract: The present invention relates to compounds and related technetium and rhenium complexes thereof which are suitable for imaging or therapeutic treatment of tumors, e.g., carcinomas, melanomas and other tumors. In another embodiment, the invention relates to methods of imaging tumors using radiolabeled metal complexes. Preferred radiolabeled complexes for imaging tumors include technetium and rhenium complexes. The high tumor uptake and significant tumor/nontumor ratios of the technetium complexes of the invention indicate that such small technetium-99m-based molecular probes can be developed as in-vivo diagnostic agents for melanoma and its metastases. In yet another embodiment, the invention relates to methods of treatment of tumors using a radiolabeled metal complex as a radiopharmaceutical agent to treat the tumor.Type: ApplicationFiled: January 21, 2008Publication date: September 18, 2008Inventors: Ashfaq Mahmood, Matthias Friebe, Cristina Bolzati, Alun G. Jones, Alan Davison
-
Patent number: 7396523Abstract: The present invention provides radioactive metal heterocomplexes of formula (I): [(Me?N—R)L1L2]+Z (I), wherein Me, R, L1 L2 and Z? have the meanings indicated in the description. The complexes include a trivalent radioactive metal-imido group, typically a technetium- or rhenium-imido group, strongly stabilized by the presence of an ancillary tridentate hetero-diphosphine ligand L1, which allows the formation of substitution-inert [(Me?N—R)L1] moieties. Such moieties are fixed in an intermediate [(Me?N—R)Y2L1)]+ compound which contains two labile, cispositioned, Y ligands, where Y is preferably an halide group. The latter are easily replaced by a bidentate ligand L2 to give the final [(Me?N—R)L1L2]+Z? heterocomplexes. The complexes of the invention are useful for the preparation of radiopharmaceuticals: in fact, a bioactive fragment which confers biological target-seeking properties can be introduced either on the L2 framework or the imido R group.Type: GrantFiled: October 31, 2003Date of Patent: July 8, 2008Assignee: Bracco Imaging S.p.A.Inventors: Francesco Tisato, Cristina Bolzati, Marina Porchia, Fiorenzo Refosco
-
Patent number: 7321027Abstract: The present invention relates to compounds and related technetium and rhenium complexes thereof which are suitable for imaging or therapeutic treatment of tumors, e.g., carcinomas, melanomas and other tumors. In another embodiment, the invention relates to methods of imaging tumors using radiolabeled metal complexes. Preferred radiolabeled complexes for imaging tumors include technetium and rhenium complexes. The high tumor uptake and significant tumor/nontumor ratios of the technetium complexes of the invention indicate that such small technetium-99m-based molecular probes can be developed as in-vivo diagnostic agents for melanoma and its metastases. In yet another embodiment, the invention relates to methods of treatment of tumors using a radiolabeled metal complex as a radiopharmaceutical agent to treat the tumor.Type: GrantFiled: October 23, 2002Date of Patent: January 22, 2008Assignees: President and Fellows of Harvard College, Massachusetts Institute of TechnologyInventors: Ashfaq Mahmood, Matthias Friebe, Cristina Bolzati, Alun G. Jones, Alan Davison
-
Publication number: 20060120957Abstract: The present invention provides radioactive metal heterocomplexes of formula (I): [(Me?N—R)L1L2]+Z. (I), wherein Me, R, L1 L2 and Z? have the meanings indicated in the description. The complexes include a trivalent radioactive metal-imido group, typically a technetium- or rhenium-imido group, strongly stabilized by the presence of an ancillary tridentate hetero-diphosphine ligand L1, which allows the formation of substitution-inert [(Me?N—R)L1] moieties. Such moieties are fixed in an intermediate [(Me?N—R)Y2L1)]+ compound which contains two labile, cispositioned, Y ligands, where Y is preferably an halide group. The latter are easily replaced by a bidentate ligand L2 to give the final [(Me?N—R)L1L2]+Z?heterocomplexes. The complexes of the invention are useful for the preparation of radiopharmaceuticals: in fact, a bioactive fragment which confers biological target-seeking properties can be introduced either on the L2 framework or the imido R group.Type: ApplicationFiled: October 31, 2003Publication date: June 8, 2006Inventors: Francesco Tisato, Cristina Bolzati, Marina Porchia, Fiorenzo Refosco
-
Publication number: 20040097735Abstract: The present invention relates to compounds and related technetium and rhenium complexes thereof which are suitable for imaging or therapeutic treatment of tumors, e.g., carcinomas, melanomas and other tumors. In another embodiment, the invention relates to methods of imaging tumors using radiolabeled metal complexes. Preferred radiolabeled complexes for imaging tumors include technetium and rhenium complexes. The high tumor uptake and significant tumor/nontumor ratios of the technetium complexes of the invention indicate that such small technetium-99m-based molecular probes can be developed as in-vivo diagnostic agents for melanoma and its metastases. In yet another embodiment, the invention relates to methods of treatment of tumors using a radiolabeled metal complex as a radiopharmaceutical agent to treat the tumor.Type: ApplicationFiled: October 23, 2002Publication date: May 20, 2004Applicants: President and Fellows of Harvard College, Massachusetts Institute of TechnologyInventors: Ashfaq Mahmood, Matthias Friebe, Cristina Bolzati, Alun G. Jones, Alan Davison
-
Publication number: 20040018147Abstract: A radiopharmaceutical for diagnostic imaging containing as an active ingredient a technetium-99m nitride heterocomplex comprising technetium-99m nitride and two different ligands coordinated therewith, i.e., a bisphosphinoamine compound as a &pgr; electron acceptor and a bidentate ligand as a &pgr; electron donor and represented by the following formula (I): [99mTc(N)(PNP)(XY)]+ (I)wherein 99mTc(N) is technetium-99m nitride, PNP is a bisphosphinoamine compound and XY is a bidentate ligand, is markedly accumulated in heart and adrenal glands and hence is useful for radiodiagnostic imaging of heart and adrenal glands.Type: ApplicationFiled: September 4, 2003Publication date: January 29, 2004Inventors: Adriano Duatti, Cristina Bolzati, Licia Uccelli, Alessandra Boschi, Fiorenzo Refosco, Francesco Tisato
-
Publication number: 20020048549Abstract: The present invention provides a single radioactive transition metal nitride heterocomplex which permits labeling of a physiologically active substance such as a peptide, hormone or the like without impairing the activity of the substance.Type: ApplicationFiled: July 16, 2001Publication date: April 25, 2002Inventors: Adriano Duatti, Cristina Bolzati, Licia Uccelli, Fiorenzo Refosco, Francesco Tisato
-
Patent number: 6270745Abstract: The present invention provides a single radioactive transition metal nitride heterocomplex which permits labeling of a physiologically active substance such as a peptide, hormone or the like without impairing the activity of the substance. The radioactive transition metal nitride heterocomplex of the present invention is represented by the following formula (I): (M≡N)XY (I) wherein a radioactive transition metal M is radioactive technetium or radioactive rhenium, N is a nitrogen atom, X is a diphosphine compound or a diarsine compound, and Y is a bindentate ligand having a combination of electron-donating atoms.Type: GrantFiled: June 17, 1999Date of Patent: August 7, 2001Assignee: Nihon Medi-Physics Co., Ltd.Inventors: Adriano Duatti, Cristina Bolzati, Licia Uccelli, Fiorenzo Refosco, Francesco Tisato
-
Patent number: 6127530Abstract: The present invention relates in general to a method for the reduction of oxygenated compounds of rhenium and technetium and in particular to the reduction of perrhenate or pertechnetate ions.More particularly, the invention relates to reactions for the reduction of the said oxygenated compounds which are carried out in the course of the preparation of complexes of the radionuclides .sup.186 Re, .sup.188 Re and .sup.99m Tc; in these reactions, the radionuclide perrhenate or pertechnetate ion is reduced in the presence of a reducing agent and a ligand which can form a complex with the radionuclide in its reduced oxidation state.Type: GrantFiled: June 4, 1999Date of Patent: October 3, 2000Assignee: Nycomed Amersham Sorin S.r.l.Inventors: Adriano Duatti, Cristina Bolzati, Licia Uccelli, Rodolfo Franceschini, Alessandra Boschi